Literature DB >> 15843858

Predictors of mortality in Acinetobacter baumannii bacteremia.

Hsin Pai Chen1, Te Li Chen, Chung Hsu Lai, Chang Phone Fung, Wing Wai Wong, Kwok Woon Yu, Cheng Yi Liu.   

Abstract

This study retrospectively investigated 149 episodes of Acinetobacter baumannii bacteremia which occurred during a 41-month period from September 1997 to January 2001. Bacteremia was nosocomial in 139 (93%) of the episodes and community-acquired in 10 (7%). Thirty three deaths (22.1%) were attributed to these episodes of A. baumannii bacteremia. The mean age of survivors was younger than that of patients who died of bacteremia (60.4 +/- 19.9 vs 67.1 +/- 17.4) but this result was not significant on univariate analysis (p=0.084). Previous intensive care unit stay was longer among survivors than among patients who died of bacteremia (9.5 vs 18 days, p=0.048). Factors associated with mortality included immunosuppression (p=0.019), shock (p=0.002), recent surgery (p=0.008), invasive procedures such as central venous catheterization (p=0.002), urinary catheterization (p=0.012), placement of a nasogastric tube (p<0.001), pulmonary catheterization (p=0.015), and mechanical ventilation (p=0.035). The number of underlying conditions (p=0.015) and invasive procedures (p<0.001) were positively correlated with mortality. Mortality was significantly associated with lower platelet count (p=0.001) and lower serum albumin concentration (p=0.005). Patients with catheter-related bacteremia had a high survival rate (96.2%), while survival rate was low in patients with infection originating from the respiratory tract (60.8%). Susceptibility testing by agar dilution test indicated that imipenem was the most effective antibiotic, followed by cefepime and ciprofloxacin. The mortality rate was lower in patients who received 1 or more antibiotics to which the isolates were susceptible, but this difference was not significant (p=0.197). On multivariate analysis, factors that independently correlated with mortality were increased age (p=0.003), immunosuppressive status (p=0.001), recent surgery (p=0.002), acute respiratory failure (p=0.004), acute renal failure (p=0.009) and septic shock (p<0.001). These findings highlight the importance of a treatment strategy based on risk stratification among patients with A. baumannii bacteremia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15843858

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  26 in total

1.  Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors.

Authors:  M-C Chiang; S-C Kuo; S-J Chen; S-P Yang; Y-T Lee; T-L Chen; C-P Fung
Journal:  Infection       Date:  2011-09-02       Impact factor: 3.553

2.  Acinetobacter baumannii bacteraemia in patients with haematological malignancy: a multicentre retrospective study from the Infection Working Party of Jiangsu Society of Hematology.

Authors:  X Wang; L Zhang; A Sun; X Yang; W Sang; Y Jiang; J Cheng; J Wang; M Zhou; B Chen; J Ouyang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-18       Impact factor: 3.267

3.  Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance.

Authors:  D W Wareham; D C Bean; P Khanna; E M Hennessy; D Krahe; A Ely; M Millar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-19       Impact factor: 3.267

4.  High and increasing Oxa-51 DNA load predict mortality in Acinetobacter baumannii bacteremia: implication for pathogenesis and evaluation of therapy.

Authors:  Yu-Chung Chuang; Shan-Chwen Chang; Wei-Kung Wang
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

5.  Risk factors and outcome of Acinetobacter baumanii infection in severe trauma patients.

Authors:  Anselmo Caricato; Luca Montini; Giuseppe Bello; Vincenzo Michetti; Riccardo Maviglia; Maria G Bocci; Giovanna Mercurio; Salvatore M Maggiore; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2009-08-04       Impact factor: 17.440

Review 6.  Community-acquired Acinetobacter infections.

Authors:  M E Falagas; E A Karveli; I Kelesidis; T Kelesidis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12       Impact factor: 3.267

7.  Risk factors and outcomes for patients with bloodstream infection due to Acinetobacter baumannii-calcoaceticus complex.

Authors:  Teena Chopra; Dror Marchaim; Paul C Johnson; Reda A Awali; Hardik Doshi; Indu Chalana; Naomi Davis; Jing J Zhao; Jason M Pogue; Sapna Parmar; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

8.  Acinetobacter baylyi as a pathogen for opportunistic infection.

Authors:  Te-Li Chen; Leung-Kei Siu; Yi-Tzu Lee; Chien-Pei Chen; Li-Yueh Huang; Roy Chen-Chih Wu; Wen-Long Cho; Chang-Phone Fung
Journal:  J Clin Microbiol       Date:  2008-07-16       Impact factor: 5.948

Review 9.  Treatment options for multidrug-resistant Acinetobacter species.

Authors:  Jacob Gilad; Yehuda Carmeli
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  Stress responses in the opportunistic pathogen Acinetobacter baumannii.

Authors:  Steven E Fiester; Luis A Actis
Journal:  Future Microbiol       Date:  2013-03       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.